[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100288294":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":21,"responsibleParty":37,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":53,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Study participants",null,"No intervention",[13],{"name":14,"affiliation":5,"role":15},"Sagar U Nigwekar, MD, MMSc","PRINCIPAL_INVESTIGATOR",[17],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","617-726-7872","snigwekar@mgh.harvard.edu",[22],{"facility":5,"status":23,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":30,"coordinates":31},"Point",[32,33],-71.05977,42.35843,{"lat":33,"lon":32},[36],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},{"type":15,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Sagar U. Nigwekar, MD, MMSc","Assistant in Medicine","100288294","partners-calciphylaxis-biobank-100288294",false,"NCT03032835","Partners Calciphylaxis Biobank","Partners Calciphylaxis Biobank and Patient Registry","PCB","Inclusion Criteria:\n\n1. Male or female ≥18 years old\n2. Skin lesions consistent with calciphylaxis diagnosis as determined by the treating clinician\n3. Informed of the investigational nature of the study and sign written Informed consent OR are eligible for surrogate consent process based on impaired decision making\n\nExclusion Criteria:\n\n1. Patients \\\u003C18 years of age\n2. Prisoners","ALL","18 Years",{"count":51,"type":52},300,"ESTIMATED","20 Years","OBSERVATIONAL","Calciphylaxis, a vascular calcification disorder, is a rare and serious disorder characterized by calcification of dermal arterioles.\n\nThere are significant gaps in the understanding of the pathophysiology and risk factors for calciphylaxis. At present, there is no effective treatment. Uncertain pathobiology, rare incidence and lack of collaborative approach have been some of the major limiting factors towards treating calciphylaxis.\n\nThe Partners Calciphylaxis Biorepository (PCB) aims to address these gaps within calciphylaxis research by utilizing existing and, when necessary, developing new infrastructure to support the consent of patients and the collection of dedicated samples for a calciphylaxis repository.",[57,58,59,60],"Calciphylaxis","Calcific Uremic Arteriolopathy","End Stage Renal Disease","Chronic Kidney Diseases",[57,62,63],"Warfarin","Dialysis","2024-11-18",{"date":66,"type":67},"2024-11-19","ACTUAL",{"date":69,"type":10},"2017-01",{"date":71,"type":52},"2030-12",{"name":5,"class":6},1]